Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.61 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21828594 | 1.00 | ACE (0.61) | ACESLC7A5MAPTKDM4ETHRB | |
| SCHEMBL30311049 | 0.95 | ACE (0.56) | ACESLC7A5MAPTKDM4ETHRB | |
| SCHEMBL30288000 | 0.95 | ACE (0.56) | ACESLC7A5MAPTKDM4ETHRB | |
| SCHEMBL29721145 | 0.94 | ACE (0.54) | ACESLC7A5MAPTKDM4ETHRB | |
| SCHEMBL31357420 | 0.94 | ACE (0.54) | ACESLC7A5MAPTKDM4ETHRB | |
| SCHEMBL30123555 | 0.92 | ACE (0.53) | ACESLC7A5MAPTKDM4ETHRB | |
| SCHEMBL31720932 | 0.92 | ACE (0.51) | ACESLC7A5MAPTKDM4ETHRB | |
| SCHEMBL30288017 | 0.91 | ACE (0.51) | ACESLC7A5MAPTKDM4ETHRB | |
| SCHEMBL31589849 | 0.91 | ACE (0.51) | ACESLC7A5MAPTKDM4ETHRB | |
| SCHEMBL31753480 | 0.90 | ACE (0.50) | ACESLC7A5MAPTKDM4ETHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713340-A2 | COMPOSITIONS AND METHODS FOR PEPTIDE-BASED MODULATORS OF HUMAN PAPILLOMAVIRUS ONCOPROTEIN E6 | Calico Life Sciences LLC (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | claimed |
| CN-112891512-B | Use of polypeptide compounds for preventing or treating liver fibrosis | 清远市图微安创科技开发有限公司 | 2024-07-26 | — | — | CN | claimed |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | claimed |
| EP-4713340-A2 | COMPOSITIONS AND METHODS FOR PEPTIDE-BASED MODULATORS OF HUMAN PAPILLOMAVIRUS ONCOPROTEIN E6 | Calico Life Sciences LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4711004-A2 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4684030-A2 | METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP | Martin-Luther-Universität Halle-Wittenberg (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2025261607-A1 | PARTICLES, COMPOSITIONS AND METHODS | BioNTech SE (DE) | 2025-12-26 | — | — | WO | disclosed |
| EP-4618952-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2025-06-19 | — | — | US | disclosed |
| CN-115044652-A | Nucleic acid detection kit based on CRISPR/Cas12a system and up-conversion luminescent particle immunochromatography and application | 中国人民解放军军事科学院军事医学研究院 | 2022-09-13 | — | — | CN | disclosed |
| EP-4034243-A2 | PEPTIDE FOR TREATING CANCER | Saint Leo University (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-4029513-A1 | MELANOCORTIN-4 RECEPTOR AGONISTS FOR THE TREATMENT OF DISORDERS CHARACTERISED BY POMC GENE HYPERMETHYLATION | Rhythm Pharmaceuticals, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-107428804-B | Immunomodulator | 百时美施贵宝公司 | 2022-06-28 | — | — | CN | disclosed |
| EP-3988108-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | Rhythm Pharmaceuticals, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2022067086-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-3271373-B1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020071258-A1 | PROTEIN GLYCATION SUPPRESSANT | 味の素株式会社 | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | MC4R, NPY4R, MC3R | ACE 2940/4885SLC7A5 2049/4885MAPT 1236/4885 |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | ACE 1785/4885SLC7A5 2014/4885MAPT 3005/4885 |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | ACE 3990/4885SLC7A5 4056/4885MAPT 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.